Lilly and Samsung fueled competition in biosimilar insulin market

Biosimilar developers will now aim for the insulin market. Their target is ‘Lantus,’ the one prescribed the most.

According to the industry concerned on the 24^th, the first biosimilar of Lantus(insulin glargine) was developed by Lilly. The company acquired the sales approval of ‘Basaglar’ in Europe in 2014, and in Korea, the U.S. and Japan last year.

Samsung, too, has gotten closer to comme...